HUGE FSD Pharma
- 0.3410
- -0.0090-2.57%
FSD Pharma News
Shares of Cannabis Stocks Are Trading Higher After Biden Said the Justice Department Is Taking the Next Steps to Reclassify Marijuana From Schedule I to Schedule III.
Shares of Cannabis Stocks Are Trading Higher After Biden Said the Justice Department Is Taking the Next Steps to Reclassify Marijuana From Schedule I to Schedule III.
President Biden Posts On X "Too Many Lives Have Been Upended Because Of Our Failed Approach To Marijuana. So Today, The @TheJusticeDept Is Taking The Next Step To Reclassify Marijuana From A Schedule I To A Schedule Iii Drug Under Federal Law."
President Biden Posts On X "Too Many Lives Have Been Upended Because Of Our Failed Approach To Marijuana. So Today, The @TheJusticeDept Is Taking The Next Step To Reclassify Marijuana From A Schedule
FSD Pharma Unveils Unbuzzd's Fresh New Look
FSD Pharma | 6-K: Report of foreign private issuer (related to financial reporting)
'DEA Appears To Question Marijuana's Medical Value Despite Rescheduling Recommendation' - Marijuana Moment
'DEA Appears To Question Marijuana's Medical Value Despite Rescheduling Recommendation' - Marijuana Moment
FSD Pharma Advances MS Treatment Trials
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent And Established Law And Regulations (Two Confidential...
Newsweek Reporter Kevin Sabet Says On X "I Can Now Say With Full Confidence That The Administrator Of DEA, Anne Milgram, Did Not Sign The Rescheduling Order, Breaking With Five Decades Of Precedent An
'Declassifying Cannabis Still Leaves Pot Stocks In Limbo' - Wall Street Journal
'Declassifying Cannabis Still Leaves Pot Stocks In Limbo' - Wall Street Journal
FSD Pharma Trials Supplement for Alcohol Intoxication
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
DEA Moving To Reclassify Marijuana As Less Dangerous Drug
FSD Pharma Says Celly Nutrition Partners With Six+One for US Launch of Dietary Supplement
FSD Pharma (HUGE) said Thursday that Celly Nutrition has partnered with branding agency Six+One to collaborate on the launch of its dietary supplement unbuzzd in the US. As part of the collaboration,
FSD Pharma's Unbuzzd Gears Up for U.S. Launch
FSD Pharma Provides Update From Celly Nu's Partnership With Six+One For Beverage Product Unbuzzd
On April 25, 2024, Celly Nu announced a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City. FSD Pharma has also licensed unbuzzd,
FSD Pharma Gears Up for Unbuzzd US Launch
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of Unbuzzd(TM)
On April 22, 2024, Celly Nu announced a strategic partnership with BevSource, a leading provider of beverage development, production and operations solutions in St. Paul, Minnesota as follows.
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
FSD Pharma Says It Has Initiated Investigations Into Ingredients And Dietary Supplements That May Have The Potential To Promote Weight Loss And Liver Health
FSD Pharma Says It Has Initiated Investigations Into Ingredients And Dietary Supplements That May Have The Potential To Promote Weight Loss And Liver Health
FSD Pharma Increases Stake in Recovery Drink Innovator
FSD Pharma Provides Update on Its Investment in Celly Nutrition Corp., a Company Launching a Product That Can Assist in Expediting Alcohol Metabolism and Faster Recovery From Alcohol Consumption
On April 8, 2024, Celly Nu announced an investment by FSD complete press release is referenced below;
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Analysis
Price Target
No Data
